Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping. - Wikidata - wikimedia - TriplyDB

Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping.

Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping.

http://www.wikidata.org/entity/Q38320074

about

Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to date Epidemiology of Plasmodium vivax Malaria in Peru New developments in anti-malarial target candidate and product profiles Variation in Human Cytochrome P-450 Drug-Metabolism Genes: A Gateway to the Understanding of Plasmodium vivax Relapses Current therapies and future possibilities for drug development against liver-stage malaria.Fixed-Dose Artesunate-Amodiaquine Combination vs Chloroquine for Treatment of Uncomplicated Blood Stage P. vivax Infection in the Brazilian Amazon: An Open-Label Randomized, Controlled Trial.Modelling primaquine-induced haemolysis in G6PD deficiency.Methods for the field evaluation of quantitative G6PD diagnostics: a review.High prevalence of very-low Plasmodium falciparum and Plasmodium vivax parasitaemia carriers in the Peruvian Amazon: insights into local and occupational mobility-related transmission Substantial population structure of Plasmodium vivax in Thailand facilitates identification of the sources of residual transmission.Malaria Epidemiology at the Clone Level.malERA: An updated research agenda for diagnostics, drugs, vaccines, and vector control in malaria elimination and eradication.Tackling resistance: emerging antimalarials and new parasite targets in the era of elimination Chloroquine resistance is associated to multi-copy pvcrt-o gene in Plasmodium vivax malaria in the Brazilian Amazon

P2860

Q26741307-51A1B1AE-4453-4E71-B2FC-ACCC1FAB4EDD Q28355360-4F2ABDB2-2B13-4B9A-B599-32E88BDB3582 Q28468598-5B8DA32F-2D12-4D8A-9720-172294E577A3 Q28553162-A5205DCC-EF4F-4F49-BB70-12147F4ED86A Q36951722-A4411459-EEE3-4935-9A20-F79420B41414 Q37560437-50717767-06CC-4455-A29F-DACE566A7435 Q37672066-3C533C68-B299-4E5D-A6AB-2B9C5E0076BD Q40053271-5FD9529E-7267-44F6-AB31-CE6D6A8D7DD4 Q42379248-22133C8E-E2A0-4D5D-B21D-991CF7672FED Q45781005-5D14E9F0-E7DF-49A8-8971-7DBDBDBB3C82 Q46014409-9FA6BC3F-1DE6-4B27-A252-776A4D335108 Q47134819-DC7BB18D-625B-444F-9E66-3E721DC3F85A Q56350408-06C7D70C-70E3-4FE5-B0A0-3F7F58F1C450 Q56361832-C24120A9-6725-4EEE-A6B9-C1717A098F41

P2860

Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping.

http://www.wikidata.org/entity/Q38320074

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping.

@en

type

label

Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping.

@en

prefLabel

Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping.

@en

P1433

Q38320074-E14C9071-9A59-4C12-9200-B5FE66AC0C43

P1476

Q38320074-A5DB0760-C4A4-4E10-BD57-6C02535C267C

P2093

Q38320074-04A00D5E-1230-4B3F-97D3-907BEE20AFC3

Q38320074-286EFABD-FC3B-4571-BE44-CC0B94434302

Q38320074-33D7F447-F4F8-44D9-BA69-1C1605CEE966

Q38320074-5F9BF57D-FB33-4C53-B8CC-FB92A29D8621

Q38320074-93BA3611-C8D4-4990-A7BC-6C03E3AB45FF

Q38320074-B034A461-A0A3-4496-97D2-2D7D58AD4D27

Q38320074-EF154038-AEB0-4FF4-B9CC-A56B63E6FC51

P2860

Q38320074-488203C6-C258-48EB-B2D4-D18A46653D4A

Q38320074-7B68BE5D-5C7C-4E3F-B63E-2F3373A54446

Q38320074-7F437BFD-7C04-48B4-AE74-D1548A2ACA41

Q38320074-83E2493C-E254-431E-9ADC-07387F4A7722

Q38320074-8CA8FBD9-29E4-4183-826F-6FE8B36A8978

Q38320074-B11EBB51-989C-4EEF-949A-2FF1ECCA25CE

Q38320074-B7F09F3E-AAAF-417A-92C1-039BF30D4FC5

Q38320074-D41812FD-FD73-4195-89F5-1D5137FC5895

Q38320074-D9574CA3-59D2-4CDE-ABD3-64F058F41684

Q38320074-D967A8DD-633F-4618-A8EE-CA23FE700A05

P304

Q38320074-00360978-0409-41C1-8909-DF2E8F281FE8

P31

Q38320074-8192B534-5BFC-4C5A-892C-401413CDA0A9

P356

Q38320074-A490AD95-21AE-4991-95B3-6E4410F115A2

P407

Q38320074-404B609C-C088-4C55-9C29-DA00A6EDA573

P433

Q38320074-29C6B1D5-EDBD-4D45-B02E-4719E29B6EC8

P478

Q38320074-58405B33-5CAD-417A-8B6C-3680423923D7

P50

Q38320074-2E1645D8-CD79-47B7-897B-EADD2A1C14AE

Q38320074-44971A4C-7D9F-4C52-92D1-969255C43625

Q38320074-B7B4480D-172E-4976-807C-9042F836EBF1

Q38320074-BC47B296-20F3-4357-AC82-D7D68D3FED8F

Q38320074-CF9291A8-956C-4EB4-A040-04D609A125CF

P577

Q38320074-B0E9C16E-D18E-4DB2-9359-3D5EE77BAB10

P5875

Q38320074-48536F49-138B-4831-98C3-AC67D94F3536

P698

Q38320074-A2622109-22EB-4C66-A509-C1DDF1433459

P921

Q38320074-9A247603-7C62-411A-85DE-B6E3E71F12CC

P932

Q38320074-FA6A9FB1-6ADC-4E9F-AB03-E1C6EAEAF0EE

P356

P1433

The Journal of Infectious Diseases

P1476

Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping

@en

P2093

Justin A Green

http://www.w3.org/2001/XMLSchema#string

Marcus V Lacerda

http://www.w3.org/2001/XMLSchema#string

Nick Carter

http://www.w3.org/2001/XMLSchema#string

Rahel Wampfler

http://www.w3.org/2001/XMLSchema#string

Ronnatrai Rueangweerayut

http://www.w3.org/2001/XMLSchema#string

Srivcha Krudsood

http://www.w3.org/2001/XMLSchema#string

Stephan Duparc

http://www.w3.org/2001/XMLSchema#string

P2860

Duffy negative antigen is no longer a barrier to Plasmodium vivax--molecular evidences from the African West Coast (Angola and Equatorial Guinea)

Killing the hypnozoite--drug discovery approaches to prevent relapse in Plasmodium vivax

ama1 genes of sympatric Plasmodium vivax and P. falciparum from Venezuela differ significantly in genetic diversity and recombination frequency.

Multilocus genotyping reveals high heterogeneity and strong local population structure of the Plasmodium vivax population in the Peruvian Amazon.

Multiplicity and diversity of Plasmodium vivax infections in a highly endemic region in Papua New Guinea

The global public health significance of Plasmodium vivax.

Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.

Using Amplicon Deep Sequencing to Detect Genetic Signatures of Plasmodium vivax Relapse.

Microsatellite genotyping of Plasmodium vivax infections and their relapses in pregnant and non-pregnant patients on the Thai-Myanmar border.

Evaluation of Plasmodium vivax genotyping markers for molecular monitoring in clinical trials.

P304

794-799

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/INFDIS/JIV508

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

213

http://www.w3.org/2001/XMLSchema#string

P50

Hans-Peter Beck

Gavin C K W Koh

Alejandro Llanos-Cuentas

P577

2015-10-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

283260968

http://www.w3.org/2001/XMLSchema#string

P698

26500351

http://www.w3.org/2001/XMLSchema#string

P921

Plasmodium vivax

P932

4747625

http://www.w3.org/2001/XMLSchema#string